Pre-Made Anakinra Biosimilar, Recombinant Protein targeting IL1R1: Recombinant therapeutic protein targeting CD121A/D2S1473/IL-1R-alpha/IL1R/IL1RA/P80 for drug discovery and mechanism of action (MOA) research

Pre-Made Anakinra Biosimilar, Recombinant Protein targeting IL1R1: Recombinant therapeutic protein targeting CD121A/D2S1473/IL-1R-alpha/IL1R/IL1RA/P80 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Anakinra, sold under the brand name Kineret, is a biopharmaceutical medication used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still’s disease.[3] It is a recombinant and slightly modified version of the human interleukin 1 receptor antagonist protein.[3] It is marketed by Swedish Orphan Biovitrum.[1] Anakinra is administered by subcutaneous injection.[2]

Anakinra is used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes, familial Mediterranean fever, and Still’s disease. Anakinra is a recombinant, non-glycosylated human interleukin-1 receptor antagonist (IL-1Ra). The anakinra has an extra methionine residue at the amino terminus compared to the native human IL-1Ra. Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.